drugset / Trial / NCT00086580

Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients

NCT00086580

Phase 3 Completed 335 enrolled Genzyme, a Sanofi Company
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a Phase 3, prospective, multicenter, open-label, randomized, controlled study to evaluate and compare the efficacy and safety of fludarabine plus alemtuzumab versus fludarabine alone as second-line therapy for patients with relapsed or refractory B-cell chronic lymphocytic leukemia (B-CLL). Patients who meet all eligibility criteria and sign the informed consent document may be entered on the study.

Timeline

Start
2004-07
Primary completion
2010-06
Completion
2010-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Alemtuzumab Monoclonal antibody 30 mg Intravenous
Comparator Fludarabine Small molecule 25 mg/m2 Intravenous
Comparator Fludarabine Small molecule 30 mg/m2 Intravenous